Why the study?
Does lisinopril improve hemodynamic and hormonal parameters in patients with chronic stable congestive heart failure?
Does lisinopril improve hemodynamic and hormonal parameters in patients with chronic stable congestive heart failure?
Lisinopril demonstrates potent ACE inhibition and favorable hemodynamic effects lasting over 24 hours in patients with congestive heart failure, despite reduced oral absorption compared to normal volunteers.
Answers are grounded in this paper and cite their sources.
May support hemodynamic relief in stable CHF; leaves open outcome benefits and needs randomized confirmation.
The acute hemodynamic, hormonal, and pharmacokinetic aspects of treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril were assessed in two studies in 24 patients with chronic stable congestive heart failure (CHF). Lisinopril, the lysine analogue of enalaprilat, is biologically active following absorption and is cleared via the urine without any known metabolic transformation. In the hemodynamic study, single doses of lisinopril (1.25–10.0 mg) were administered on days 1 and 3, each followed by 48 h of intensive hemodynamic observation in 12 patients. Arterial and mixed venous blood from the right atrium were sampled frequently and assayed for angiotensin I, angiotensin II, ACE activity, plasma renin activity, renin substrate, plasma aldosterone, and serum drug concentration. Across all doses, reductions in mean arterial pressure (-17.2%), mean pulmonary capillary wedge pressure (-28.0%), and systemic vascular resistance (-25.6%) were observed compared to baseline values. No significant changes in heart rate or cardiac index were observed. The analysis of the hormonal parameters indicate potent inhibition of the renin-angiotensin-aldosterone system for a period exceeding 24 h. In the pharmacokinetic study, 12 hospitalized patients with chronic CHF received lisinopril both orally and intravenously, with each dose followed by a 72-h arterial blood and urine sampling schedule. Arterial blood pressure was monitored continuously for 6 h following each dosage using an intraarterial cannula. Mean urinary recovery of lisinopril was found to be 15% following oral administration and 88% following intravenous administration. Maximal serum drug concentration occurred at 6 h after oral drug. As compared to data obtained from normal volunteers, the results suggest reduced absorption in patients with CHF. However, the CHF patients showed higher serum concentrations than normals following intravenous (i.v.) administration. The maximal hypotensive responses after i.v. lisinopril (-24 ± 10 mm Hg at 75 min) were comparable to oral lisinopril (- 19 ± 13 mm Hg at 210 min), although the time course profiles were markedly different. Although oral absorption of lisinopril is low in patients with CHF, our results indicate potent ACE inhibition along with hemodynamic efficacy over a period exceeding 24 h.
No takes yet. Share an insight, caveat, or question.
Kenneth Dickstein (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: